EXPRESSION OF OSTEOPONTIN AND OSTEONECTIN IN BREAST AND PROSTATE CANCER CELLS WITH DIFFERENT SENSITIVITY TO DOXORUBICIN.

Q3 Medicine

Experimental oncology Pub Date : 2022-08-01 DOI:10.32471/exp-oncology.2312-8852.vol-44-no-2.17886

T Zadvornyi, N Lukianova, T Borikun, S Gogol, P Virych, O Lykhova, V Chekhun

{"title":"EXPRESSION OF OSTEOPONTIN AND OSTEONECTIN IN BREAST AND PROSTATE CANCER CELLS WITH DIFFERENT SENSITIVITY TO DOXORUBICIN.","authors":"T Zadvornyi, N Lukianova, T Borikun, S Gogol, P Virych, O Lykhova, V Chekhun","doi":"10.32471/exp-oncology.2312-8852.vol-44-no-2.17886","DOIUrl":null,"url":null,"abstract":"Background: According to modern literature, osteopontin (OPN) and osteonectin (ON) are involved not only in the formation of the aggressive phenotype of malignantly transformed cells, but also in the realization of cytotoxic effects of some antitumor drugs.Aim: To study the changes of the expression of OPN and ON and their mRNAs (SPP1 and SPARC) upon exposure to doxorubicin (Dox) in breast cancer (BCa) and prostate cancer (PCa) cell lines with different sensitivity to Dox.Materials and methods: Cell lines of BCa (MCF-7 and MDA-MB-231) and PCa (LNCaP and DU-145) were cultured in the presence of Dox at IC30 concentrations for 24 h. OPN and ON levels were assessed by immunocytochemical (ICH) and Western blot analysis. SPP1 and SPARC mRNA levels were assessed by quantitative PCR.Results: Dox treatment resulted in the significant decrease in the expression of both OPN and ON in MCF-7 and LNCaP cells. Similarly, Dox treatment downregulated both SPP1 and SPARC in MDA-MB-231 and DU-145 cells. Dox did not affect ON expression in MDA-MB-231 and DU-145 cells although the significant decrease in the level of SPARC mRNA has been evident. In contrast, no significant differences in SPP1 and SPARC mRNA levels were detected in LNCaP cells.Conclusion: The changes in the expression of OPN and ON proteins and their corresponding genes in BCa and PCa cells may be related to the intrinsic mechanisms of Dox effects in cells differing by malignant phenotype and Dox sensitivity.","PeriodicalId":12287,"journal":{"name":"Experimental oncology","volume":"44 2","pages":"107-112"},"PeriodicalIF":0.0000,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Experimental oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32471/exp-oncology.2312-8852.vol-44-no-2.17886","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 1

Abstract

Background: According to modern literature, osteopontin (OPN) and osteonectin (ON) are involved not only in the formation of the aggressive phenotype of malignantly transformed cells, but also in the realization of cytotoxic effects of some antitumor drugs.

Aim: To study the changes of the expression of OPN and ON and their mRNAs (SPP1 and SPARC) upon exposure to doxorubicin (Dox) in breast cancer (BCa) and prostate cancer (PCa) cell lines with different sensitivity to Dox.

Materials and methods: Cell lines of BCa (MCF-7 and MDA-MB-231) and PCa (LNCaP and DU-145) were cultured in the presence of Dox at IC30 concentrations for 24 h. OPN and ON levels were assessed by immunocytochemical (ICH) and Western blot analysis. SPP1 and SPARC mRNA levels were assessed by quantitative PCR.

Results: Dox treatment resulted in the significant decrease in the expression of both OPN and ON in MCF-7 and LNCaP cells. Similarly, Dox treatment downregulated both SPP1 and SPARC in MDA-MB-231 and DU-145 cells. Dox did not affect ON expression in MDA-MB-231 and DU-145 cells although the significant decrease in the level of SPARC mRNA has been evident. In contrast, no significant differences in SPP1 and SPARC mRNA levels were detected in LNCaP cells.

Conclusion: The changes in the expression of OPN and ON proteins and their corresponding genes in BCa and PCa cells may be related to the intrinsic mechanisms of Dox effects in cells differing by malignant phenotype and Dox sensitivity.

查看原文本刊更多论文

骨桥蛋白和骨连接素在阿霉素敏感性不同的乳腺癌和前列腺癌细胞中的表达。

背景:根据现代文献，骨桥蛋白(osteopontin, OPN)和骨连接蛋白(osteonectin, ON)不仅参与了恶性转化细胞侵袭表型的形成，还参与了一些抗肿瘤药物的细胞毒性作用的实现。目的:研究不同阿霉素敏感性乳腺癌(BCa)和前列腺癌(PCa)细胞株中OPN和ON及其mrna SPP1和SPARC在阿霉素(Dox)作用下的表达变化。材料和方法:将BCa (MCF-7和MDA-MB-231)和PCa (LNCaP和DU-145)细胞株在IC30浓度Dox存在下培养24 h，采用免疫细胞化学(ICH)和Western blot分析OPN和ON水平。定量PCR检测SPP1和SPARC mRNA表达水平。结果:Dox处理导致MCF-7和LNCaP细胞中OPN和ON的表达显著降低。同样，Dox处理下调MDA-MB-231和DU-145细胞中的SPP1和SPARC。Dox不影响MDA-MB-231和DU-145细胞ON的表达，但SPARC mRNA水平明显下降。相比之下，LNCaP细胞中SPP1和SPARC mRNA水平无显著差异。结论:BCa和PCa细胞中OPN和ON蛋白及其对应基因的表达变化可能与不同恶性表型和Dox敏感性细胞中Dox效应的内在机制有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Experimental oncology Medicine-Oncology

CiteScore

1.40

自引率

0.00%

发文量

期刊介绍： The Experimental Oncology is an English-language journal that publishes review articles, original contributions, short communications, case reports and technical advances presenting new data in the field of experimental and fundamental oncology. Manuscripts should be written in English, contain original work, which has not been published or submitted for publication elsewhere. It also implies the transfer of the Copyright from the author to “Experimental Oncology”. No part of journal publications may be reproduced, stored in a retrieval system or transmitted in any form or by any means without the prior permission of the publisher.